On September 6, 2022 Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), reported that the Company’s leadership will participate in the following investor conferences (Press release, Orum Therapeutics, SEP 6, 2022, View Source [SID1234619034]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Morgan Stanley 20th Annual Global Healthcare Conference
Forum: 1×1 In-Person Meetings
Dates: Monday, September 12th to Wednesday, September 14, 2022Location: New York, NY
Baird’s Global Healthcare Conference 2022
Forum: Presentation and 1×1 In-Person Meetings
Dates: Tuesday, September 13th to Wednesday, September 14, 2022
Location: New York, NYThe presentation will take place at 4:20 pm ET on September 13th.
UBS Virtual Biotechnology Private Company Symposium
Forum: 1×1 Virtual Meetings
Date: Wednesday, September 21 to Thursday, September 22, 2022
About Orum’s GSPT1 Platform Using the TPD²Approach
Orum’s GSPT1 platform uses the Company’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach to build novel targeted protein degraders (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to cancer cells and degrade the intracellular target protein GSPT1 and cause tumor cell death.